Threshold Pharmaceuticals, Inc (THLD): Opiniones

el mio en estos momentos un poco más de 900€

A los que estáis en o seguís Zalicus, os he dejado una cosita (en el hilo correspondiente, of course)

S2

Más que nada, por ver si el hilo sigue activo... porque casi 2h sin que nadie diga ni mu...

A los aficionados al AT, confirmo que los graficos del hilo USA son en tiempo real (eso sí, como Yahoo, Google y otro, hay que irle dando a actualizar) e incluyen mogollón de líneas que a mi no me dicen nada, pero que en AT al parecer sirven de algo http://investorshub.advfn.com/boards/board.aspx?board_id=6387

S2

Yo sigo al pie del cañon, pero estoy viendo un clásico.
EL PADRINO

Gracias Jorge!! el hilo esta paradisimo... Veo que tu estas al pie del cañon :))

Referring to Threshold Pharmaceuticals(THLD), @holdiday613 asks, "Any opinions on the TH-302 data?"
The phase II data presented this week on Threshold's pancreatic cancer drug TH-302 were essentially in line with results pre-announced in February: A two-month benefit in progression-free survival from 5.6 months in the TH-302+gemcitabine arm compared to 3.6 months in the gemcitabine-alone arm. It was good see a positive dose response in the trial; better still will be an overall survival benefit, but we need to wait for later in the year for that data to mature.
Relatively few patients in the gemcitabine arm crossed over to take TH-302, which may bode well for the survival analysis. Risks to a survival benefit: Some imbalances between the patient groups in the study, including performance status, which may have skewed the PFS benefit in TH-302's favor. Median overall survival for TH-302 in the 10-month range would be viewed positively.
Threshold shares sold off this week, but that's not unexpected given the huge gains since the initial TH-302 results were announced in February. Threshold was the top-performing biotech stock in the first quarter.
Looking ahead, watch to see if Threshold can convince FDA allow an approval filing based on this phase II study. It's a long shot, so I wouldn't count on it happening, but still, an early filing in pancreatic cancer without the need for a larger phase III trial would definitely send Threshold shares higher.
Threshold is also conducting a phase III study of TH-302 in soft tissue sarcoma, with interim results expected by the end of the year.
If you're interested in a sarcoma drug stock that hasn't yet had a big run, take a look at Ziopharm(ZIOP) and its drug palifosfamide. Data from a phase III study are expected in the second half of the year.
--Written by Adam Feuerstein in Boston.

Buenas noticias , solo que se necesita plazo.

eso parece buenas noticias salvo que Don Jorge A tenga mejor criterio...

me estoy pensando un tirito pequeño a 7,10...la verdad es que la vuelta de enola que sube la moral!!!

Pues tu alter ego en este foro si que usa el AT :)

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=74069530